For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

A federal judge in Massachusetts ruled on Monday that directives from the Trump administration that led to the cancellations ...

F or the past 60 years, a committee of independent experts has advised the federal government on vaccine policy, providing ...

COVID-19 appears to be on the rise in some parts of California as a new, highly contagious subvariant — featuring 'razor ...

REGINA, SASKATCHEWAN / ACCESS Newswire / June 16, 2025 / Consumer Choice Award (CCA) is proud to announce that Affordable ...

TRNR is expected to have the largest US publicly listed crypto treasury focused on an AI-token TRNR began acquiring $FET in ...

Moderna’s respiratory syncytial virus (RSV) vaccine mRESVIA has been approved by the US Food and Drug Administration (FDA) ...

Planning Underway for Expedited Follow-up RC and Diamond Programs HIGHLIGHTS 2,882m reverse circulation (RC) drilling ...

New to The Street will continue its coverage with a powerful combination of national TV commercials, long-form interviews, earned media placements, and exposure on iconic outdoor billboards NEW YORK ...

The drugmaker plans to ask for FDA approval of the vaccine this year, while other pharmaceutical companies are also working on RSV vaccines. CNBC: Moderna: RSV Vaccine Effective In Preventing Disease ...

In a report released yesterday, Courtney Breen from Bernstein maintained a Hold rating on Moderna (MRNA – Research Report). The company’s shares closed yesterday at $27.35. Co ...

Piper Sandler analyst Edward Tenthoff maintained a Buy rating on Moderna (MRNA – Research Report) today and set a price target of $69.00. The company’s shares closed yesterday ...